IPP Bureau

T-CURX gets Swissmedic nod for first human trial of non-viral CAR-T therapy
T-CURX gets Swissmedic nod for first human trial of non-viral CAR-T therapy

By IPP Bureau - June 15, 2026

Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform

Ramkrishna CARE Hospitals’s dedicated cancer institute to open in August 2026
Ramkrishna CARE Hospitals’s dedicated cancer institute to open in August 2026

By IPP Bureau - June 15, 2026

The new institute will strengthen oncology infrastructure in central India with advanced radiation therapy, multidisciplinary expertise, and comprehensive cancer care services

Ajanta Pharma to hold 47th annual general meeting on July 16
Ajanta Pharma to hold 47th annual general meeting on July 16

By IPP Bureau - June 15, 2026

Company sets key dates for shareholder participation and voting as it prepares to present FY26 annual report.

Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026
Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026

By IPP Bureau - June 14, 2026

Samelisant will be the centerpiece of Suven’s scientific presence

Alembic secures USFDA nod for Tretinoin Cream strengthening generics portfolio
Alembic secures USFDA nod for Tretinoin Cream strengthening generics portfolio

By IPP Bureau - June 14, 2026

The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream

Breakthrough approval in prostate cancer for AstraZeneca therapy
Breakthrough approval in prostate cancer for AstraZeneca therapy

By IPP Bureau - June 14, 2026

The decision was driven by results from the Phase III CAPItello-281 trial,

India clears major milestone in cervical cancer fight with validation of first indigenous HPV DNA test
India clears major milestone in cervical cancer fight with validation of first indigenous HPV DNA test

By IPP Bureau - June 14, 2026

Cervical cancer remains one of the leading causes of cancer deaths among women in India

Centre intensifies push for zero leprosy transmission
Centre intensifies push for zero leprosy transmission

By IPP Bureau - June 13, 2026

Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India

India validates first indigenous HPV DNA test for cervical cancer screening
India validates first indigenous HPV DNA test for cervical cancer screening

By IPP Bureau - June 13, 2026

Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards

Ryvu advances romaciclib program as FDA clears AML trial expansion
Ryvu advances romaciclib program as FDA clears AML trial expansion

By IPP Bureau - June 13, 2026

The regulatory decision follows promising results from RIVER-81

Novo Nordisk confirms cyber breach after hackers access personal data
Novo Nordisk confirms cyber breach after hackers access personal data

By IPP Bureau - June 13, 2026

Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.

UK approves Wegovy pill in major shift in obesity treatment options
UK approves Wegovy pill in major shift in obesity treatment options

By IPP Bureau - June 13, 2026

Approval is based on results from the phase 3 OASIS 4 clinical trial

FDA clears Wave Neuroscience’s AI-guided brain stimulation platform for PTSD treatment
FDA clears Wave Neuroscience’s AI-guided brain stimulation platform for PTSD treatment

By IPP Bureau - June 13, 2026

MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms

Rayat Bahra University, Shukra Pharma launch Rs. 10 lakh seed fund to back student startups
Rayat Bahra University, Shukra Pharma launch Rs. 10 lakh seed fund to back student startups

By IPP Bureau - June 13, 2026

Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture

Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor
Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor

By IPP Bureau - June 13, 2026

Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders

Latest Stories

Interviews

Packaging